NeuroIntact Inc. Appoints Robert Kline to Board of Directors
Robert Kline ● Photo Credit: NeuroIntact Inc.
BALTIMORE, October 29, 2024 (VSNewsNetwork.com) - NeuroIntact Inc., a med-tech company specializing in targeted temperature management (TTM) for neurological conditions, has named Robert Kline to its Board of Directors. Kline, known for his pioneering work in TTM, brings 25 years of experience in medical technology and company growth to assist NeuroIntact as it progresses its TTM technology toward commercialization.
Kline founded Medivance, which developed therapeutic temperature management products aimed at improving outcomes for critical conditions, including cardiac arrest and traumatic brain injury. The company was acquired by C.R. Bard in 2011. Kline also co-founded ViroCyt, which was acquired by Sartorius AG in 2016, and served as CEO of Bolder Surgical, acquired by Hologic, Inc. in 2021. Commenting on NeuroIntact's technology, Kline stated, "NeuroIntact’s non-invasive intranasal delivery technology to cool the brain represents a sea change in TTM, and I am extremely enthusiastic about its potential. NeuroIntact’s cooling approach can be administered without the use of sedation drugs, and with the benefit of nonexistent patient shivering. As a result, I believe this will provide the proven benefit of cooling therapy to a much larger group of patients than treated today.”
NeuroIntact’s Board Chair, Bill Niland, noted the significance of Kline's appointment, adding, "Bob’s extensive experience in growing innovative medical companies will be instrumental as we advance our mission to deliver revolutionary solutions for TTM technology."
NeuroIntact Founder and President Bryan Nicholson commented, “We have intentionally cultivated a board of directors composed of proven experts in airway management and TTM. I feel so fortunate to have this amazing trust behind me to accomplish our mission of advancing the science of TTM and provide valuable solutions to healthcare providers and patients everywhere."
@VSNewsNetwork
@VSNewsNetwork
The company’s VCool™ TTM system is a non-invasive technology designed to reduce intracranial pressure and manage core body temperature without the need for sedation drugs, aiming to minimize patient shivering. It’s important to note that VCooL™ is not currently cleared for use in the United States. NeuroIntact plans to present its first human trial results on November 12, 2024, at Medica in Düsseldorf, Germany.
Learn more at www.Neurointact.com.
Source: NeuroIntact Inc.
